Effectiveness of enterovirus A71 vaccine against pediatric HFMD and disease profile of post-vaccination infection
Copyright © 2024 Elsevier Ltd. All rights reserved..
BACKGROUND: Vaccination has been proven effective against infection with enterovirus A71 (EV-A71) in clinical trials, but vaccine effectiveness in real-world situations remains incompletely understood. Furthermore, it is not clear whether previous vaccination will result in symptom attenuation among post-vaccinated cases.
METHODS: Based on long-term data extracted from the only designed referral hospital for infectious diseases, we used a test-negative case-control design and multivariate logistic regression models to analyze the effectiveness of EV-A71 vaccine against hand, foot and mouth disease (HFMD). And then, generalized linear regression models were used to evaluate the associations between prior vaccination and disease profiles.
RESULTS: We selected 4883 inpatients for vaccine efficacy estimations and 2188 inpatients for disease profile comparisons. Vaccine effectiveness against EV-A71-induced HFMD for complete vaccination was 63.4 % and 51.7 % for partial vaccination. The vaccine effectiveness was higher among cases received the first dose within 12 months. No protection was observed against coxsackievirus (CV) A6-, CV-A10- or CV-A16-associated HFMD among children regardless of vaccination status. Completely vaccinated cases had shorter hospital stay and disease course compared to unvaccinated cases (P < 0.05).
CONCLUSIONS: These findings reiterate the need to continue the development of a multivalent vaccine or combined vaccines, and have implications for introducing optimized vaccination strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Vaccine - 42(2024), 9 vom: 02. Apr., Seite 2317-2325 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Duan, Xiaoxia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vaccine.2024.02.026 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369229398 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369229398 | ||
| 003 | DE-627 | ||
| 005 | 20240408232529.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240304s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2024.02.026 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM369229398 | ||
| 035 | |a (NLM)38433065 | ||
| 035 | |a (PII)S0264-410X(24)00172-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Duan, Xiaoxia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of enterovirus A71 vaccine against pediatric HFMD and disease profile of post-vaccination infection |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Vaccination has been proven effective against infection with enterovirus A71 (EV-A71) in clinical trials, but vaccine effectiveness in real-world situations remains incompletely understood. Furthermore, it is not clear whether previous vaccination will result in symptom attenuation among post-vaccinated cases | ||
| 520 | |a METHODS: Based on long-term data extracted from the only designed referral hospital for infectious diseases, we used a test-negative case-control design and multivariate logistic regression models to analyze the effectiveness of EV-A71 vaccine against hand, foot and mouth disease (HFMD). And then, generalized linear regression models were used to evaluate the associations between prior vaccination and disease profiles | ||
| 520 | |a RESULTS: We selected 4883 inpatients for vaccine efficacy estimations and 2188 inpatients for disease profile comparisons. Vaccine effectiveness against EV-A71-induced HFMD for complete vaccination was 63.4 % and 51.7 % for partial vaccination. The vaccine effectiveness was higher among cases received the first dose within 12 months. No protection was observed against coxsackievirus (CV) A6-, CV-A10- or CV-A16-associated HFMD among children regardless of vaccination status. Completely vaccinated cases had shorter hospital stay and disease course compared to unvaccinated cases (P < 0.05) | ||
| 520 | |a CONCLUSIONS: These findings reiterate the need to continue the development of a multivalent vaccine or combined vaccines, and have implications for introducing optimized vaccination strategies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Breakthrough infection | |
| 650 | 4 | |a Disease profile | |
| 650 | 4 | |a Enterovirus A71 | |
| 650 | 4 | |a Hand, foot and mouth disease | |
| 650 | 4 | |a Vaccine effectiveness | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Antigens, Viral |2 NLM | |
| 650 | 7 | |a Vaccines, Combined |2 NLM | |
| 700 | 1 | |a Zhang, Liangzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Chaoyong |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Zhenhua |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiao |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Hongxia |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Xueqin |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Xueling |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Sufei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Yilan |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Long, Lu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 42(2024), 9 vom: 02. Apr., Seite 2317-2325 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:9 |g day:02 |g month:04 |g pages:2317-2325 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2024.02.026 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2024 |e 9 |b 02 |c 04 |h 2317-2325 | ||